$3.71
0.02[0.54%]
At close: Apr 26
$3.71
0[0.00%]
After Hours: 4:20PM EDT
MaxCyte
(NASDAQ:MXCT)Latest News for MaxCyte Stock (NASDAQ:MXCT)
MaxCyte Stock (NASDAQ: MXCT)
Categories: All
Tuesday, April 23, 2024
Tuesday, April 02, 2024
Wednesday, March 20, 2024
Wednesday, March 13, 2024
- Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $11 Price TargetBenzinga Newsdesk - Mar 13, 2024, 12:02PM
- NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For WednesdayAvi Kapoor - Mar 13, 2024, 8:51AM
- BTIG Maintains Buy on MaxCyte, Lowers Price Target to $8Benzinga Newsdesk - Mar 13, 2024, 8:03AM
- MaxCyte shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 guidance.Benzinga Newsdesk - Mar 13, 2024, 7:03AM
- Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market SessionAvi Kapoor - Mar 13, 2024, 6:16AM
Tuesday, March 12, 2024
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Mar 12, 2024, 5:33PM
- MaxCyte shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 guidance.Benzinga Newsdesk - Mar 12, 2024, 4:24PM
- MaxCyte Expects FY24 Core Business Revenue To Be Flat To 5% Growth Compared To 2023, And SPL Program-Related Revenue Is Expected To Be ~$3M; Expects To End 2024 With $175M In Total Cash, Cash Equivalents And InvestmentsBenzinga Newsdesk - Mar 12, 2024, 4:09PM
- MaxCyte Q4 EPS $(0.05) Beats $(0.07) Estimate, Sales $15.66M Beat $13.09M EstimateHappy Mohamed - Mar 12, 2024, 4:08PM
- Earnings Scheduled For March 12, 2024Benzinga Insights - Mar 12, 2024, 5:35AM
Monday, March 11, 2024
Tuesday, March 05, 2024
Monday, March 04, 2024
Tuesday, January 09, 2024
Monday, January 08, 2024
- MaxCyte shares are trading higher after the company announced strong preliminary Q4 and full year 2023 revenue results.Benzinga Newsdesk - Jan 8, 2024, 4:44PM
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga Insights - Jan 8, 2024, 4:31PM
- MaxCyte Announces Preliminary Q4 Revenue $15.5M-$15.7M Vs $10.74M Est.; FY23 Revenue $41.1M-$41.3M Vs $36.72M Est.; Total Cash, Cash Equivalents, And Investments As Of December 31, 2023 Is Expected To Be ~$210MBenzinga Newsdesk - Jan 8, 2024, 4:08PM
Wednesday, January 03, 2024
Tuesday, January 02, 2024
Wednesday, December 06, 2023
Wednesday, November 29, 2023
Wednesday, November 08, 2023
Thursday, October 05, 2023
- Cell Engineering MaxCyte Faces Challenge, Analysts Express Concerns Over Near-Term Prospects Amid Revenue DeclineVandana Singh - Oct 5, 2023, 2:35PM
- Crude Oil Down 2%; ConAgra Brands Earnings Top ViewsLisa Levin - Oct 5, 2023, 2:31PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Oct 5, 2023, 1:31PM
- Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Oct 5, 2023, 1:22PM
- Stocks That Hit 52-Week Lows On ThursdayBenzinga Insights - Oct 5, 2023, 1:22PM
- Dow Tumbles Over 100 Points; Constellation Brands Raises Profit ForecastLisa Levin - Oct 5, 2023, 12:10PM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Oct 5, 2023, 9:10AM
- MaxCyte shares are trading lower after the company said it sees a year-over-year decrease of 25 to 27 percent in preliminary Q3 total revenue.Benzinga Newsdesk - Oct 5, 2023, 8:54AM
- Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $12 Price TargetBenzinga Newsdesk - Oct 5, 2023, 8:30AM
- Why Orchard Therapeutics Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving PremarketLisa Levin - Oct 5, 2023, 8:15AM
- MaxCyte, Rivian Automotive And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionLisa Levin - Oct 5, 2023, 6:03AM
- Conagra Brands, Constellation Brands And 3 Stocks To Watch Heading Into ThursdayLisa Levin - Oct 5, 2023, 5:08AM
Wednesday, October 04, 2023
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga Insights - Oct 4, 2023, 5:31PM
- MaxCyte shares are trading lower after the company said it sees a year-over-year decrease of 25 to 27 percent in preliminary Q3 total revenue.Benzinga Newsdesk - Oct 4, 2023, 4:23PM
- MaxCyte Sees Prelim. Q3 Total Revenue 7.8M-$8M, Down 27% YoY; Says Decline Is Due To Continued Reduced Customer Activity In The SectorBill Haddad - Oct 4, 2023, 4:06PM